Peptide News Digest

PCAC Docket Closes With 1,860 Comments, Novo Sues Lilly Over GLP-1 Ads, Trump Generic Tariff Plan

PCAC docket closes tonight, Hims CMO to testify; Novo sues Lilly on GLP-1 ads; Trump 100% generic drug tariff; Samsung Bioepis-IntoCell ADC deal; Lonza strong H1 earnings.

6 stories · Covering regulatory, industry

Editor's Note

Wednesday's digest catches four running-story cutoffs converging at once. The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes tonight at 11:59 PM ET with approximately 1,860 public comments filed, and Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at the Thursday July 23 hearing while acknowledging the 'relatively sparse clinical evidence' for the seven peptides under review. Novo Nordisk sued Eli Lilly Tuesday July 21 in federal court alleging 'deceptive' advertising practices around GLP-1 drug efficacy claims, per STAT News reporting. President Trump announced a phased 100% tariff on imported generic drugs starting August 2028 with a two-year grace period, a policy that directly affects the Sandoz generic tirzepatide ANDAs accepted by the FDA on June 29 and the Indian generic semaglutide launches that Biocon, Dr. Reddy's, and Hetero rolled out in March-April 2026. Samsung Bioepis and IntoCell announced a commercial license agreement for the SBE303 Nectin-4-targeting antibody-drug conjugate. Lonza reported H1 2026 sales of CHF 3.37 billion (+16% constant exchange rate) and CHF 595 million profit, driven partly by 27.7% CER growth in the Advanced Synthesis division that houses small-molecule and bioconjugate manufacturing. And NPR published a nationally syndicated feature Wednesday extending the mainstream media wave into the eve of the PCAC vote.

FDA Pharmacy Compounding Advisory Committee Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Tonight Wednesday July 22 With Approximately 1,860 Public Comments Filed on the Seven-Peptide Review (BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, and Epitalon); Hims Chief Medical Officer Dr. Anant Vinjamoori Confirmed Hims Will Testify at the Thursday July 23 Hearing and Publicly Acknowledged the 'Relatively Sparse Clinical Evidence for These Peptides' While Confirming Hims Plans to Offer the Peptides If the FDA Reclassifies Them

The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.

Novo Nordisk Sues Eli Lilly in Federal Court on Tuesday July 21 Alleging 'Deceptive' Advertising Practices in GLP-1 Drug Marketing (Per STAT News Reporting); The Complaint Targets Advertising Claims That Novo Says Make Eli Lilly's Zepbound (Tirzepatide) and Mounjaro (Tirzepatide) Franchises Appear More Effective Than the Underlying Clinical Data Support Versus Novo's Wegovy (Semaglutide) and Ozempic (Semaglutide) Franchises

Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).

President Trump Announces Tuesday July 21 That Imported Generic Drugs Will Face Zero Tariffs for Two Years Starting August 1, 2026 Before a 100% Levy Takes Effect in August 2028 and Rises to 200% One Year Later — The Phased Schedule Is Designed to Push Generic Drugmakers to Onshore US Manufacturing; The Policy Directly Affects the Sandoz Generic Tirzepatide ANDAs Accepted by the FDA on June 29 and the Indian Generic Semaglutide Launches That Biocon, Dr. Reddy's, and Hetero Rolled Out in March-April 2026

President Donald Trump announced Tuesday July 21, 2026 via social media that imported generic drugs will face zero tariffs for two years starting August 1, 2026 before a 100% levy takes effect in August 2028 and rises to 200% one year later. Trump described the escalation as 'a penalty' for companies that do not build manufacturing plants in the US within the grace period. India is the largest exporter of generic medicines to the US ($10.5 billion in fiscal year 2024-25), with pharmaceuticals among India's top three exports to America. Companies with the greatest exposure include Teva, Viatris, and Apotex, all of which manufacture a large share of US-sold products overseas. Sandoz (Novartis' generic subsidiary), which had two Abbreviated New Drug Applications for generic tirzepatide (Mounjaro and Zepbound) accepted by the FDA on June 29, 2026, told CNBC it was 'too early to assess' the proposal because 'further details on the implementation and scope of the measure are still required.' The tariff timeline collides with the tirzepatide patent expiration (2036 in the US) and the Indian generic semaglutide launches from Biocon, Dr. Reddy's, and Hetero that rolled out in March-April 2026. Patented and branded drugs remain unchanged under the April 2 Section 232 100% patented pharma tariff.

NPR Nationally Syndicated Feature Wednesday July 22: 'FDA Panel to Consider Easing Restrictions on Peptide Production' — The Story Extends the Mainstream-Media Wave Into the Eve of the July 23-24 PCAC Vote, Following NPR's July 8 Feature ('What's Behind the Push to Make Peptide Therapies More Readily Available'), the July 9 Washington Post Health Brief ('The Peptide Showdown'), and the July 21 Forbes Op-Ed by Dr. Omer Awan ('FDA's Review of Peptides Signals a Growing Public Health Challenge')

NPR published a nationally syndicated feature Wednesday July 22, 2026 titled 'FDA panel to consider easing restrictions on peptide production,' extending the mainstream-media wave into the eve of the July 23-24 PCAC vote. The feature is NPR's second major peptide policy piece in two weeks, following the July 8 nationally syndicated 'What's behind the push to make peptide therapies more readily available.' The pre-vote mainstream media cycle now includes the July 8 NPR feature, the July 9 Washington Post Health Brief 'The peptide showdown' by Megan R. Wilson, the July 17 Washington Post FDA conflict-of-interest report, the July 21 Forbes op-ed by Dr. Omer Awan ('FDA's Review of Peptides Signals a Growing Public Health Challenge — Separating Science from Hype'), and the July 22 NBC News explainer 'What to know about the seven peptides an FDA advisory panel is set to review this week.' Regional NPR affiliates and public media stations (WFAE Charlotte, Wyoming Public Media, WVAS FM, WJCT Jacksonville, and KPBS San Diego) picked up the syndication under the alternate title 'Peptides get their regulatory closeup.' The coverage volume signals that the story has moved past the trade press (Endpoints, STAT, FiercePharma) and into general-audience awareness heading into the two-day vote.

Samsung Bioepis and Korean Biotech IntoCell Announce Wednesday July 22 a Commercial License Agreement for SBE303, a Nectin-4-Targeting Antibody-Drug Conjugate Currently in Phase 1 Clinical Development in the US and Korea for Advanced Refractory Solid Tumors With Planned Enrollment of 149 Patients Through July 2030; The Deal Extends Samsung Bioepis's Shift From Biosimilar Manufacturing Into Novel-Drug Development Through Joint Research and Licensing With IntoCell and China's Frontline

Samsung Bioepis and Korean biotech IntoCell announced Wednesday July 22, 2026 that they have entered into a commercial license agreement for SBE303, one of the antibody-drug conjugate (ADC) candidates the two companies are jointly developing. SBE303 is a next-generation ADC cancer treatment targeting the Nectin-4 protein, combining Samsung Bioepis's proprietary humanized antibody with IntoCell's linker platform and a payload originally developed by IntoCell under patent license from China's Frontline. Samsung Bioepis is currently conducting a global Phase 1 clinical trial of SBE303 in the United States and Korea, with plans to evaluate safety and preliminary efficacy in 149 patients with advanced refractory solid tumors through July 2030. The deal extends Samsung Bioepis's strategic shift from a biosimilar manufacturer to a novel-drug developer, and adds to the July 2026 payload-and-conjugate consolidation wave alongside Novartis's July 6 $1.5 billion Myricx Bio acquisition (NMTi payload platform), Lonza's July 2 Nona Biosciences TfR1 blood-brain-barrier deal, SOTIO's July 14 FDA Fast Track Designation for SOT109 (CDH17 ADC), and Simris Group's July 16 appointment of former Heidelberg Pharma CEO Andreas Pahl to lead its cyanobacterial microcystin ADC payload platform.

Lonza Reports H1 2026 Earnings Wednesday July 22: CHF 3.37 Billion in Sales (+11.2% AER, +16.0% Constant Exchange Rate), CHF 595 Million Profit (Versus CHF 426 Million H1 2025), CHF 1.2 Billion Core EBITDA (+27.4% YoY) at a 34.8% Margin (+4.4 Percentage Points); Advanced Synthesis Division (Housing Small-Molecule and Bioconjugate Manufacturing) Delivered 27.7% CER Sales Growth Driven by Small-Molecule and Bioconjugate Demand — Lonza Also Confirmed the CDMO Capacity Expansion in Stein, Switzerland Following a Major-Pharma ADC Clinical and Commercial Manufacturing Agreement

Lonza (SIX: LONN) reported first-half 2026 earnings Wednesday July 22, 2026: sales of CHF 3.37 billion (up 11.2% at actual exchange rate, up 16.0% at constant exchange rate), CHF 595 million profit (CHF 8.18 per share) versus CHF 426 million (CHF 5.68 per share) in H1 2025, and CHF 1.2 billion core EBITDA (up 27.4% year-over-year) at a 34.8% margin (up 4.4 percentage points). The Advanced Synthesis division, which houses small-molecule and bioconjugate manufacturing, delivered 27.7% CER sales growth driven by demand for small-molecule and bioconjugate products; the Integrated Biologics division grew 10% CER. Lonza lifted its full-year 2026 margin outlook and confirmed CDMO capacity expansion in Stein, Switzerland following a major-pharma ADC clinical and commercial manufacturing agreement. The Lonza H1 print, combined with the July 20 Samsung Biologics $1.8 billion PolyPeptide tender offer and the July 2 Lonza-Nona Biosciences TfR1 BBB deal, sustains the peptide- and biologic-CDMO consolidation thesis that has run through the first half of 2026. Peptide-based GLP-1 manufacturing capacity constraints continue to drive premium CDMO pricing.